Mulato A S, Ho E S, Cihlar T
Gilead Sciences, Foster City, California, USA.
J Pharmacol Exp Ther. 2000 Oct;295(1):10-5.
Adefovir is a nucleotide analog with anti-human immunodeficiency virus (HIV) activity that has been extensively studied in clinical trials. While on prolonged anti-HIV therapy with adefovir, some patients may develop drug-associated nephrotoxicity manifested by changes in laboratory markers of renal tubular functions that are reversible upon drug discontinuation. It has been recently shown that adefovir is efficiently transported by the human renal organic anion transporter 1 (hOAT1), a membrane transport protein localized in the kidney, that presumably mediates the accumulation of adefovir in renal proximal tubules. In an effort to look for novel inhibitors of this transport process, we used a cell line stably expressing hOAT1 to demonstrate that nonsteroidal anti-inflammatory drugs (NSAIDs) efficiently inhibit hOAT1-specific transport of adefovir at clinically relevant concentrations. Diflunisal, ketoprofen, flurbiprofen, indomethacin, naproxen, and ibuprofen were equally or more effective (IC(50) = 0.85-8 microM) than probenecid or betamipron, two known potent inhibitors of hOAT1 (IC(50) = 8 and 6 microM, respectively) with in vivo nephroprotective effects. Importantly, NSAIDs significantly reduced the shift in adefovir cytotoxicity observed upon hOAT1 expression with ketoprofen and naproxen being 2- to 3-times more effective than probenecid. Transport experiments with [(3)H]ketoprofen and [(3)H]ibuprofen revealed that NSAIDs themselves were not efficiently transported by hOAT1. None of the NSAIDs tested showed any interference with the anti-HIV activity of adefovir. In conclusion, these observations suggest that NSAIDs may reduce or delay the emergence of adefovir nephrotoxicity.
阿德福韦是一种具有抗人类免疫缺陷病毒(HIV)活性的核苷酸类似物,已在临床试验中得到广泛研究。在用阿德福韦进行长期抗HIV治疗时,一些患者可能会出现药物相关的肾毒性,表现为肾小管功能实验室指标的变化,停药后这些变化是可逆的。最近的研究表明,阿德福韦可被人肾有机阴离子转运体1(hOAT1)有效转运,hOAT1是一种定位于肾脏的膜转运蛋白,可能介导阿德福韦在近端肾小管中的蓄积。为了寻找这种转运过程的新型抑制剂,我们使用了稳定表达hOAT1的细胞系来证明,非甾体抗炎药(NSAIDs)在临床相关浓度下可有效抑制hOAT1介导的阿德福韦特异性转运。双氟尼酸、酮洛芬、氟比洛芬、吲哚美辛、萘普生和布洛芬比丙磺舒或倍他米隆更有效(IC50 = 0.85 - 8 microM),丙磺舒和倍他米隆是两种已知的hOAT1强效抑制剂(IC50分别为8和6 microM),具有体内肾保护作用。重要的是,NSAIDs显著降低了hOAT1表达后观察到的阿德福韦细胞毒性变化,其中酮洛芬和萘普生的效果比丙磺舒高2至3倍。用[3H]酮洛芬和[3H]布洛芬进行的转运实验表明,NSAIDs本身不能被hOAT1有效转运。所测试的NSAIDs均未显示对阿德福韦的抗HIV活性有任何干扰。总之,这些观察结果表明,NSAIDs可能会降低或延迟阿德福韦肾毒性的出现。